INTRODUCTION
For centuries, agents derived from natural sources, especially plants have been the primary source of medicine. Neem, also referred to as Azadirachta indica is one such plant that has been so named because it provides freedom from all diseases and used for thousands of years in Indian and African continents. [1] The United States has also recognized the significance of research on neem and published a report entitled "Neem-a tree for solving global problems." [2] A. indica A. Juss (Neem) is a tropical evergreen tree (Fam. Meliacae; Subfam. Melioideae) has universally been accepted as a wonder tree because of its diverse utility and multitude of human benefits in various fields. Multidirectional therapeutic uses of neem have been known in India since the Vedic times. Different parts of the plant including flowers, leaves, seeds, and bark have been used to treat both acute and chronic human diseases; and used as insecticide; antimicrobial, larvicidal, antimalarial, antibacterial, antiviral, and spermicidal. It is widely used also for its cosmetic, medicinal, and agricultural uses. [3] A. indica, commonly known as neem, has attracted worldwide prominence in recent years. Neem has been extensively used in Ayurveda, Unani, and Homoeopathic medicine and has become a cynosure of modern medicine. More than 140 compounds have been isolated from different parts of neem. All parts of the neem tree have been used conventionally for the treatment of inflammation, infections, fever, skin diseases, and dental disorders. [4] Different parts of the neem tree are used to treat pyrexia, headache, ulcer, respiratory disorders, cancer, diabetes, leprosy, malaria, dengue, chicken pox, and dermal complications. The tree is popular for its pharmacological attributes such as hypolipidemic, antifertility, microbicidal, antidiabetic, anti-inflammatory, hepatoprotective, antipyretic, hypoglycemic, insecticidal, nematicidal, antiulcer, antioxidant, neuroprotective, cardioprotective, and antileishmaniasis properties. A. indica is also rich in various phytochemicals for pharmaceuticals such as alkaloids, steroids, flavonoids, terpenoids, fatty acids, and carbohydrates. [5] The chemopreventive and anticancer therapeutic efficacy of A. indica fractions and compounds could be explained by multiple cellular and molecular mechanisms, including free radical scavenging, carcinogen-detoxification, DNA repair, cell cycle alteration, programmed cell death (apoptosis) and autophagy, immune surveillance, anti-inflammatory, anti-angiogenic, anti-invasive, and anti-metastatic activities as well as their ability to modulate several dysregulated oncogenic signaling pathways. [6] 
Literature review
Few bibliometric studies made a bibliometric assessment of Azadirachta research in the past. Thirumagal and Ramesh [7] explored global neem research (392 papers) during 2006-2010. It used PubMed database and focused on various aspects: growth rate, authorship pattern-number of authors, productivity and degree of collaboration, bibliographic format, language-wise and country-wise distribution, identification of core journals using Bradford law, and depicting a clustering view of neem research. Singh [8] examined global Azadirachta research (1198 papers) during 1901-2014. It also used PubMed and focused on chronological growth of literature, authorship pattern and author productivity, fitness of distribution of papers to Bradford's law of scattering, country-wise contribution and identification of core journals. Vijayakumar and Shehbaz [9] studied the authorship pattern of A. indica literature, which revealed that collaborative research is more favored than the solo research with a degree of collaboration as 0.94. Similar bibliometric studies have been published on other individual medicinal plants such as Aloe Vera, [10] Curcuma longa [11] Glycyrrhiza glabra, [12] Ocimum Santum, [13] Pheonix dactylifera, [14] Tinospora cordifolia, [15] and Phyllanthis emblica.
[16]
Objectives
The study examines global A. indica research performance, in terms of quantitative and qualitative indicators during 22 years (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) , based on publications indexed in the Scopus database. Its objectives are as follows: (i) to study the growth and distribution of global literature on A. indica, (ii) to examine the scientometric profile and characteristics of the 10 most productive countries, 25 most productive organizations, and to 25 most productive authors, (iii) to study the distribution of publication output by broad subject areas and identification of significant keywords, (iv) to identify the medium of communication and the bibliographic characteristics of global highly cited publications on A. indica.
METHODOLOGY
The top 10 most productive countries global publications on A. indica were sourced from Scopus international database (http://www.scopus.com), using two keywords "Azadirachta indica" or "neem" for the years 1997-2016. The TITLE-ABS-KEY (as shown in search string below) tag was searched for the two keywords restricting the hit to the period 1997-2016 in "date range" tag. The statement becomes the main search string. The main search string was further restricted to individual 10 countries in "country" tag one by one for obtaining publication data of these countries. On further restricting global search string by "subject area tag," "country tag," "source title tag," "journal title name" and "affiliation tag," statistics on the distribution of publications by subject, collaborating countries, author-wise, organization-wise and journal-wise, etc., were obtained. Citation data were obtained from the date of publication to January 25, 2018. Select bibliometric indicators have been used to study the performance of global A. indica research.
TITLE-ABS-KEY (Azadirachta indica or neem) AND PUBYEAR > 1996 AND PUBYEAR < 2017.
Analysis
The total research output of the world in the field of A. indica cumulated to 4900 publications in 20 years during 1997-2016. 
Subject-wise distribution of research output
The global A. indica research output published during 1997-2016 is distributed across eight sub-fields (as identified Table 6 ].
Significant keywords
Around 44 significant keywords having the potential to identify comparative research trends in A. indica research studies including pharmacological properties and medicinal uses were discovered from the global literature on A. indica. These keywords are listed in Table 7 in the decreasing order of the frequency of their occurrence in the literature during 1997-2016.
Highly cited papers
Seventy-eight highly cited papers in A. indica research were identified each having 100-1441 citations (50 papers each in citation range 100-199, 23 papers each in 200-499 Among 78 highly cited papers, the largest participation was seen from India (42 papers), followed by the USA (11 papers), UK (7 paper), Canada (5 papers), Brazil, Germany, and Nigeria (3 papers each), Bangladesh, Kenya, and Pakistan (2 papers each), Croatia, Costa Rica, Denmark, Ghana, Hong Kong, Japan, Malaysia, South Africa, South Korea, Spain, Thailand, Tongo, and Uganda (1 paper each). These 78 highly cited papers involved the participation of 242 personal authors and 116 research organizations in total globally. Of the 78 highly cited Conclusively, this research study reveals that developing countries (India, Brazil, Nigeria, Pakistan, China, Egypt, and Malaysia) dominate in A. indica search more in terms of quantity of research, whereas western countries (USA, UK, and Germany) dominate instead more in terms of quality of research. It is suggested that the developing countries and India, in particular, need to give higher priority to plant based research and needs to coordinate, monitor and prioritize their R and D efforts, with higher investment (both financial and manpower) in R and D and increase their international collaboration, with a view to increase their research output and improved research impact.
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